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AbstrAct
Pompe’s disease (PD) is a metabolic myopathy caused by the accumulation of lysosomal 
glycogen, secondary to acid α-glucosidase (GAA) enzyme deficiency. Childhood and late-
onset forms are described, differing by the age of onset and symptoms. In this study 
were analyzed affected siblings with Pompe’s disease (PD) and their distinct clinical and 
pathological presentations. Method: Diagnosis was performed by the clinical presentation 
of limb-girdle dystrophies and respiratory compromise. Confirmatory diagnoses were 
conducted by muscle biopsy, GAA activity measurement and by GAA gene genotyping. 
results: The findings suggested muscular involvement due to GAA deficiency. GAA 
genotyping showed they are homozygous for the c.-32-3C>A mutation. conclusion: Herein 
we reported a family where three out of five siblings were diagnosed with late-onset PD, 
although it is a rare metabolic disease inherited in an autossomal recessive manner. We 
emphasize the importance of including this presentation within the differential diagnoses 
of the limb-girdle dystrophies once enzyme replacement therapy is available. 
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Mutação homozigótica intrônica no gene gAA em três irmãos com doença de Pompe 
de início tardio
resuMo
A doença de Pompe (DP) é uma miopatia originada do acúmulo lisossomal de glicogênio, 
devido à deficiência da enzima α-glicosidase ácida (GAA), sendo descritas formas de 
inicio precoce e tardio. Neste estudo analisamos retrospectivamente o perfil clinico e 
patológico de 3 irmãos portadores de doença de Pompe de inicio tardio. Método: O 
diagnóstico foi realizado mediante apresentação clinica de distrofia de cinturas associado 
a comprometimento respiratório, sendo confirmado por biópsia muscular e análise 
da atividade e genotipagem da GAA. resultados: Os exames clínicos e laboratoriais 
demonstram envolvimento muscular devido à deficiência da GAA, com uma mutação c.-
32-3C>A em homozigose. conclusão: Relatamos os aspectos clínicos e laboratoriais de 3 
irmãos afetados por doença de Pompe de início tardio. Enfatizamos a importância de incluir 
esta patologia no diagnóstico diferencial das distrofias de cinturas, uma vez que para esta 
patologia específica existe a possibilidade terapêutica através de reposição enzimática.
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Pompe’s disease (PD), also known as 
acid maltase deficiency, is a glycogen stor-
age disease type II. It is a metabolic myo-
pathy caused by the accumulation of lys-
osomal glycogen, inherited as a recessive 
disorder1. It was first described in 1932 by 
the Dutch pathologist Johannes Cassian-
us Pompe, in a female child who died at 7 
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months of age due to hypertrophic cardiomyopathy, con-
sidered to be idiopathic at that time. In 1963, Hers and cols. 
described the acid α-1,4-glucosidase (GAA) enzyme with-
in the lysosomes, and correlated its deficiency with PD2.
Classical or early-onset PD is characterized by glob-
al hypotonia (floppy infant), marked cardiomyopathy, in 
children with less than 2 years of age. Subsequently, pa-
tients older than 2 year-old presenting progressive mus-
cular weakness, as in limb-girdle muscular dystrophy, 
without cardiomyopathy were classified as late-onset PD. 
These patients may also present spine deformities, and re-
spiratory compromise due to intercostal muscles, and di-
aphragm weakness. The final phenotype is in part modu-
lated by the GAA enzymatic activity, which is complete-
ly deficient in early-onset cases, and partially deficient 
in late-onset cases. The progression of the disease is in-
exorable in early-onset PD, and death overcome within 
the first two years of life. On the other hand, phenotyp-
ic heterogeneity is related to variable quantity of residu-
al GAA activity in late-onset cases3. This natural histo-
ry of PD, specially in early-onset form, has been modi-
fied by introduction of the human recombinant GAA (hr-
GAA) enzymatic replacement therapy (ERT), approved 
by the American Food and Drug Administration on Feb-
ruary, 2008. Survival time has been extended in early-on-
set PD4,5, and although the follow-up time for late-onset 
PD is not yet long enough to any consistent observation, 
some improvement of motor and respiratory functions 
have been observed6,7. Correct diagnosis of PD becomes 
mandatory, once a specific treatment is now available. It is 
also important to retrieve underdiagnosed late-onset PD 
among those presenting LGMD-like phenotype8-10.
Therefore, the aims of the present study are: (1) report 
three siblings presenting LGMD-like phenotype with late-
onset PD, and (2) present an intronic GAA gene mutation 
in homozigosity, a condition not reported previously.
METHOD
Three siblings from a family of five children were an-
alyzed retrospectively. Electroneuromyography (ENMG), 
spirometry, polysomnography, and measurements of cre-
atine phosphokinase (CK) and GAA activity in dry-blood 
spot11 were analyzed. Muscular biopsy was performed in 
two patients. GAA gene genotyping was studied as re-
ported previously12, and briefly was done as follows: ge-
nomic peripheral blood DNA samples had the coding re-
gion and the intron/exon boundaries of the GAA gene 
amplified by PCR and subsequently sequenced on an ABI 
PRISM 3130 DNA Sequencer using BigDye v.3.1 (Applied 
Biosystem, Foster City, CA). 
The study was approved by the Ethics Committee of 
Santa Rosa Hospital, and all members of the family stud-
ied signed an informed consent.
RESULTS
In a family of five siblings, three, one female, and two 
males, 47, 43 and 45 years of age, presented difficulties in 
climbing stairs, standing-up, and frequent drops starting 
on thirties (Table). Limb-girdle muscular dystrophy was 
the diagnosis attributed to them, based on elevated se-
rum level of CK (Table), muscle biopsy, and ENMG per-
formed in two of them showing nonspecific atrophic al-
terations, and myopathic pattern, respectively. The cor-
rect diagnosis was only established after six years from 
the onset of symptoms in the oldest sister (Case 1), who 
started presenting dyspnea at mild efforts. Restrictive 
ventilatory disturbance was detected on spirometry. She 
evolved to respiratory failure in the following year, and 
required invasive mechanic ventilation with continuous 
Bi-Pap through a tracheostomy. The association of prox-
imal limb-girdle muscle weakness, mainly in lower limbs, 
to weakness of respiratory muscle lead to the hypothe-
sis of PD, which was confirmed by GAA enzymatic mea-
Table. Findings in a family.
Case
gender
Onset of 
symptoms 
(years)
age at 
diagnosis 
(years)
actual 
age 
(years)
ERT 
(months)
Clinical findings
Respiratory 
function ENMg
CK 
(26-155 U/l)
gaa activity
Site of 
weakness MRC
Inhibition %
(<40%)
N/a
(<40)
1
F 
32 46 47 12 LGM III BIPAP Myopathic 197 87.02 43.54
2
M 
31 40 43 12 LGM III/IV Obstructive 
apnea
Myopathic 1449 89.0 52.24
3
M
43 44 45 12 LGM IV Moderate 
Restrictive 
disorder
Normal 673 91.6 55.71
F: female; M; male; ERT: enzymatic replacement therapy; LGM: limb-girdle muscle; MRC: scale of muscle strength testing according to Medical Research Council; 
ENMG, electroneuromyography; CK, creatine phosphokinase; N/A: ration between neutral and acid GAA.
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surement in dry blood spot (Table), and GAA genotyp-
ing. This diagnosis was also confirmed in the other two 
sibs (Cases 2 and 3) by both biochemichal and molecu-
lar methods. Although the brothres presented no clini-
cal respiratory complaint, further investigation of respi-
ratory function by polysomnography and spirometry re-
vealed obstructive apnea, and moderate restrictive disor-
der, respectively (Table). All three affected sibs presented 
the intron 1 (c.-32-3C>A) mutation in GAA gene in ho-
mozygosis. Each parent presented this mutation in one 
of the alleles, and it was not detected in the other two as-
ymptomatic sibs. hrGAA ERT was started upon the con-
firmation of PD, and they have received the medication 
for a period of one year. Clinical and laboratorial follow-
ups have been done regularly to monitor disease evolu-
tion and response to therapy.
DISCUSSION
We report a family with three affected siblings with 
late-onset PD, harboring an intronic mutation in ho-
mozigozity, a condition not described previously. It is in-
teresting to emphasize the intrafamiliar phenotypic het-
erogeneity. Although the onset of symptoms was similar 
among them, around their thirties, they presented dif-
ferent degree of respiratory compromise. Sibling pheno-
type discordance in late-onset PD has been described by 
others, where 10 years difference in age of onset between 
affected sibs or different clinical symptoms were detect-
ed, attesting a spectrum of clinical presentation even in a 
similar genetic background as in a single sibship13,14. Oth-
er non-genetic factors as lifestyle, nutrition, other genetic 
modifiers, and environmental factors might contribute to 
explain such clinical inter and intra-familiar variability.
The present report also stresses the importance of 
considering late-onset PD among the differential diag-
nosis of limb-girdle muscle weakness15-17. As the reliabili-
ty of CK level is low, since values vary broadly in PD8, and 
muscle biopsy may be normal in up to 30% in late-onset 
PD18, more specific testing is fundamental for the diag-
nosis. The first screening for PD could be done by GAA 
enzymatic measurement in dried blood spot, with results 
obtained in 1-2 days11. Then, the confirmation of PD diag-
nosis should be complemented by GAA biochemical as-
say in fibroblast cells or skeletal muscle sample or geno-
typing that are more costly and requires longer period of 
time for the results17.
The correct diagnosis of PD is fundamental as spe-
cific treatment is currently available. GAA enzymatic re-
placement therapy (ERT) has been proved to be well tol-
erated. Although the follow-up time since the introduc-
tion of ERT in our patients is still short to allow any con-
clusion, no evolvement of the clinical findings were ob-
served. Longer follow-up of the present cases will fur-
ther contribute to evaluate the response to ERT in 
late-onset PD.
The homozygotic c.32-3C>A intron 1 mutation de-
tected in affected sibs is an inedit contribution, as this 
condition has not previously reported. This c.-32-3C>A 
mutation was recently described by our group and 
others12,19,20, and it leads to a deletion of 579 bp, predict-
ing an anomalous transcript which would translate into 
a shorter peptide lacking the first 182 amino acids of the 
protein (p.M1_T182) comprising the 27 residues of sig-
nal sequence, the 42 residues of the propeptide and the 
first 113 amino acids of the mature protein (from 70 to 
182). Thus, factors which control splice site selection may 
contribute to the relative normal transcript level generat-
ed by the mutant allele, possibly explaining the absence of 
symptoms up to three decades in our patients. This mu-
tation has been described in combinantion with a mis-
sense mutation, c.1655T>C, in an early-onset PD21, and 
with c.1447G>A missense mutation, in late-onset PD by 
our group11. However, a homozygotic condition of a in-
tronic mutation might be rare, as such a condition was 
not yet detected even for the most common intronic c.-
31-13T>G mutation in late-onset PD3,21.
In summary, this is the first description of a homozy-
gotic intronic GAA mutation in three siblings of late-onset 
Pompe’s disease presenting a limb-girdle muscle weakness 
associated to variable degree of respiratory disfunction.
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